On its third-quarter 2026 earnings call, held on Oct. 28, 2026, Bausch + Lomb (NYSE:BLCO) announced that revenue grew 8% on a constant-currency basis to $1.375 billion. For long-term investors, sustained growth across pharmaceutical, surgical, and vision care businesses demonstrates broad commercial traction across diverse eye care markets. Three things management said stand out. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA), a key measure of core operating profitability, expanded as higher-margin product sales grew faster than operating expenses. Operating cash flow reached $233 million in the quarter, enabling Bausch + Lomb to pay down debt and lower its net leverage ratio toward its strategic target.
CryptoAlerta — análise de criptomoedas e mercado em tempo real